Zdrowie i gospodarka · 27/08/1997

FDA Releases Guidance on Reporting Postmarketing Adverse Experiences for Human Drugs and Biological Products

The Food and Drug Administration (FDA) has published a guidance document to clarify the requirements for reporting postmarketing adverse experiences for human drugs and licensed biological products, aiming to improve the quality of safety reports and streamline postmarketing surveillance.